Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?

Merkel cell carcinoma is an aggressive neuroendocrine skin cancer that usually affects elderly patients. Despite being uncommon, incidence has been steadily increasing over the last two decades, likely due to increased awareness, better diagnostic methods and aging of the population. It is currently...

Full description

Bibliographic Details
Main Author: Guilherme Rabinowits
Format: Article
Language:English
Published: MDPI AG 2014-05-01
Series:Cancers
Subjects:
Online Access:http://www.mdpi.com/2072-6694/6/2/1180
_version_ 1797709331889651712
author Guilherme Rabinowits
author_facet Guilherme Rabinowits
author_sort Guilherme Rabinowits
collection DOAJ
description Merkel cell carcinoma is an aggressive neuroendocrine skin cancer that usually affects elderly patients. Despite being uncommon, incidence has been steadily increasing over the last two decades, likely due to increased awareness, better diagnostic methods and aging of the population. It is currently one of the most lethal cutaneous malignancies, with a five-year overall survival of approximately 50%. With the better understanding of the molecular pathways that lead to the development of Merkel cell carcinoma, there has been an increasing excitement and optimism surrounding novel targeted therapies, in particular to immunotherapy. Some of the concepts surrounding the novel targeted therapies and currently ongoing clinical trials are reviewed here.
first_indexed 2024-03-12T06:35:59Z
format Article
id doaj.art-50bdb2eaa2394474ac63dd517397aa5c
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-12T06:35:59Z
publishDate 2014-05-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-50bdb2eaa2394474ac63dd517397aa5c2023-09-03T01:20:51ZengMDPI AGCancers2072-66942014-05-01621180119410.3390/cancers6021180cancers6021180Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?Guilherme Rabinowits0Dana-Farber Cancer Institute, Harvard Medical School, Department of Medical Oncology, Center for Head and Neck Oncology, 450 Brookline Avenue, Boston, MA 02215, USAMerkel cell carcinoma is an aggressive neuroendocrine skin cancer that usually affects elderly patients. Despite being uncommon, incidence has been steadily increasing over the last two decades, likely due to increased awareness, better diagnostic methods and aging of the population. It is currently one of the most lethal cutaneous malignancies, with a five-year overall survival of approximately 50%. With the better understanding of the molecular pathways that lead to the development of Merkel cell carcinoma, there has been an increasing excitement and optimism surrounding novel targeted therapies, in particular to immunotherapy. Some of the concepts surrounding the novel targeted therapies and currently ongoing clinical trials are reviewed here.http://www.mdpi.com/2072-6694/6/2/1180Merkel cell carcinomamerkel cell polyomavirusimmunotherapytargeted therapy
spellingShingle Guilherme Rabinowits
Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
Cancers
Merkel cell carcinoma
merkel cell polyomavirus
immunotherapy
targeted therapy
title Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
title_full Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
title_fullStr Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
title_full_unstemmed Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
title_short Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
title_sort systemic therapy for merkel cell carcinoma what s on the horizon
topic Merkel cell carcinoma
merkel cell polyomavirus
immunotherapy
targeted therapy
url http://www.mdpi.com/2072-6694/6/2/1180
work_keys_str_mv AT guilhermerabinowits systemictherapyformerkelcellcarcinomawhatsonthehorizon